When a small-cap or clinical-stage biotechnology company secures regulatory approval from the U.S. Food and Drug Administration, its stock price can sometimes experience a sharp sell-off or downward correction due to a phenomenon colloquially known as "selling the news." During the developmental run-up to the regulatory decision, speculative traders often accumulate shares rapidly, driving valuations higher based entirely on anticipated success. Once the approval is officially granted, these short-term investors frequently lock in their profits by liquidating positions. Additionally, newly approved biopharmaceutical firms almost immediately launch secondary public equity offerings, warrant issuances, or convertible debt placements to raise the massive capital required for commercial drug manufacturing, marketing infrastructure, and nationwide sales distribution, which heavily dilutes existing shareholders and exerts immediate downward pressure on the stock price.